Healthcare - Biotechnology - NASDAQ - US
$ 8.01
-8.98 %
$ 445 M
Market Cap
-4.77
P/E
CASH FLOW STATEMENT
-118 M
OPERATING CASH FLOW
144 M
INVESTING CASH FLOW
1.78 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Foghorn Therapeutics Inc.
| Net Income | -98.4 M |
| Depreciation & Amortization | 3.45 M |
| Capital Expenditures | -1.22 M |
| Stock-Based Compensation | 16.2 M |
| Change in Working Capital | -41.9 M |
| Others | -40.2 M |
| Free Cash Flow | -119 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (98.4) | (108.9) | (101.3) | (68.8) | (51.1) | (26.3) |
| Depreciation & Amortization | 3.5 | 3.3 | 3.2 | 1.3 | 0.7 | 0.4 |
| Deferred Income Tax | 0 | 0 | 1.4 | 84 K | 10 K | 30 K |
| Stock Based Compensation | 16.2 | 14.3 | 8.4 | 3.0 | 1.7 | 0.7 |
| Other Operating Activities | 2.6 | 3.3 | 4.6 | 4.4 | 1.2 | 0.1 |
| Change in Working Capital | (41.9) | 281.5 | 33.4 | 28.7 | 1.2 | 2.4 |
| Cash From Operations | (118.1) | 193.6 | (50.2) | (31.3) | (46.3) | (22.6) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.2) | (1.2) | (3.3) | (16.2) | (1.0) | (1.5) |
| Other Items | 145.7 | (243.1) | 39.5 | (92.7) | 4 K | 0 |
| Cash From Investing Activities | 144.4 | (244.3) | 36.2 | (108.9) | (1.0) | (1.5) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | (21.2) | 4.3 | 8.0 | 11.1 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.8 | 1.8 | 1.4 | 91.1 | 16.0 | 40.6 |
| Cash From Financing Activities | 1.8 | 1.8 | 22.4 | 217.5 | 24.0 | 51.8 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 28.1 | (48.9) | 8.3 | 77.3 | (23.3) | 27.6 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (119.3) | 192.4 | (53.6) | (47.5) | (47.3) | (24.2) |